Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib and S-1 in Recurrent/Metastatic HNSCC
NCT03096184Phase 2Unknown
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Dec 2016
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib in head and neck squamous cell carcinoma (HNSCC), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03096184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03096184.